Table 1.
Clinical features of patients at time of diagnosis.
| Age at diagnosis (years) | Median (Q1–Q3) | 68 (35–85) |
|---|---|---|
| Gender | Male | 43 (41%) |
| Female | 63 (59%) | |
| Smoking | No | 66 (62%) |
| Yes | 7 (7%) | |
| Ex | 28 (26%) | |
| nd | 5 (5%) | |
| PS | 0 | 46 (43%) |
| 1 | 55 (52%) | |
| 2 | 3 (3%) | |
| nd | 2 (2) | |
| Stage at diagnosis | I–II | 10 (9.5%) |
| III–IV | 90 (90.5%) | |
| Baseline EGFR mutation status | Exon 19 deletion | 64 (60%) |
| Ex 21 mutations (L858R) | 35 (33%) | |
| Others | 7 (7%) | |
| Type of treatment | Gefitinib | 54 (51%) |
| Erlotinib | 26 (24.5%) | |
| Afatinib | 26 (24.5%) | |
| Best response to TKI | CR | 1 (1%) |
| PR | 71 (67%) | |
| SD | 18 (17%) | |
| PD | 11 (10%) | |
| nd | 5 (5%) | |
| T790M status at progressive disease | T790M positive | 35 (33%) |
| T790M negative | 71 (67%) | |
| PFS (months) | Mean (CI 95%) | 24.30 (19.29–29.31) |
| TTF (months) | Mean (CI 95%) | 41.44 (29.45–53.39) |
| OS (months) | Mean (CI 95%) | 67.98 (51.07–84.89) |
| Total | 106 |
nd, no determined.